

Review of: "FDA Decision to Authorize NJOY ACE Menthol Was Based on a Rigorous Review of the Science to Determine That the Benefits Outweigh the Risk"

Andreas Nussler¹

¹ BG Klinik Tübingen, Tübingen, Germany

Potential competing interests: This reviewer has collaborated with Philip Morris International in the past

This brief article effectively highlights the FDA's decision to authorize NJOY menthol-flavored e-cigarettes as a harm reduction tool for adult smokers, grounded in scientific evidence. However, it could benefit from a more balanced examination of the risks to youth, a deeper exploration of menthol's specific impacts, and acknowledgment of potential long-term risks. The article's defense of NJOY products may overshadow the broader public health debate, leading to concerns about bias.

Moreover, the author should clearly present potential 'Conflict of Interest'